Dr. Abbey Spoke About the VERONA Diabetic Macular Edema Clinical Trial at The Retina Society’s Annual Meeting
On behalf of the VERONA study investigators, Texas Retina’s Ashkan M. Abbey, MD, delivered a presentation titled “VERONA: End-of-Study Results from a Phase 2 Trial of EYP-1901 (vorolanib intravitreal insert) versus Aflibercept
read more
Why We Dilate Your Eyes
Patients often ask why we must dilate their eyes. A dilated retina exam is essential to properly diagnosing and monitoring a number of retina conditions, including diabetic retinopathy, macular degeneration and retinal tears or detachment. Your
read more
Dr. Abbey Discusses How Vorolanib Could Shift the Treatment Approach for Diabetic Macular Edema in New Retinal Physician Article
Texas Retina’s Ashkan M. Abbey, MD, served as a principal site investigator for the Phase II VERONA clinical trial evaluating the efficacy and safety of the vorolanib intravitreal insert (EYP-1901) in diabetic
read more
Welcome Rocío Díaz, MD!
Texas Retina is pleased to welcome board-certified ophthalmologist and retina specialist Rocío Díaz, MD, to our practice on June 4, 2025. Serving patients in our Wichita Falls office, she will provide care
read more
Can Ozempic Affect Your Eyes or Vision?
Initially approved by the U.S. Food and Drug Administration (FDA) to help control blood sugar and treat type 2 diabetes, semaglutide (brand names Ozempic, Wegovy and Rybelsus) has also emerged as a
read more
Happy New Year!
Happy New Year! Our offices will be closed on Wednesday, January 1, 2025. As another year comes to a close, we want to thank all of our patients, referring physicians, neighbors and
read more
Dr. Abbey Publishes Case Report on Management of Cystoid Macular Edema in Coats’ Disease
Texas Retina’s Ashkan M. Abbey, MD, recently co-authored a case report in the medical journal Ophthalmic Surgery, Lasers and Imaging Retina (OSLI Retina) on the use of an injectable flucocinolone implant for
read more
Recent Study Published in Journal of Clinical Oncology Highlights Importance of Prognostic Biomarker for Uveal Melanoma
The results of the Collaborative Ocular Oncology Study Number 2 (COOG2) were published in the July 2024 issue of the Journal of Clinical Oncology and validated the prognostic accuracy of the integrated
read more

